THE PROSTATIC ENDOCRINE-PARACRINE (NEUROENDOCRINE) REGULATORY SYSTEM AND NEUROENDOCRINE DIFFERENTIATION IN PROSTATIC-CARCINOMA - A REVIEW AND FUTURE-DIRECTIONS IN BASIC RESEARCH

被引:74
作者
DISANTAGNESE, PA [1 ]
COCKETT, ATK [1 ]
机构
[1] UNIV ROCHESTER, MED CTR, DEPT UROL, ROCHESTER, NY 14642 USA
关键词
PROSTATIC NEOPLASMS; NEUROENDOCRINOLOGY; NEUROSECRETORY SYSTEMS; ENDOCRINOLOGY;
D O I
10.1016/S0022-5347(17)32417-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Endocrine-paracrine (neuroendocrine, amine precursor uptake and decarboxylation [APUD]) cells of the prostate-urethral region are serotonin and peptide containing regulatory cells, which are part of a dispersed neuroendocrine regulatory system also known as the APUD system. These cells most likely regulate growth and differentiation, as well as the secretory functions of the prostate. Prostatic carcinoma exhibits neuroendocrine differentiation in 3 forms: 1) small cell neuroendocrine carcinoma, 2) carcinoid-like tumors and 3) conventional prostatic adenocarcinoma with focal neuroendocrine differentiation. Small cell carcinoma and carcinoid-like tumors are rather rare (1 to 2% of all prostatic malignancies) and generally pursue an aggressive course. Focal neuroendocrine differentiation in adenocarcinoma is extensive in 10% of the cases and may be present in virtually all adenocarcinomas to a minor degree. There are conflicting studies on the prognostic significance of focal neuroendocrine differentiation in prostatic carcinoma, although several suggest a poor prognosis. The finding that serum neuroendocrine markers predict initial insensitivity to or the development of resistance to hormonal suppression therapy, coupled with the recent observation that androgen receptor is not expressed in neoplastic neuroendocrine cells suggests that neuroendocrine differentiation directly results in resistance to hormonal manipulation therapy. Neuroendocrine differentiation in prostatic carcinoma raises the possibility of innovative modes of treatment. Future directions of research should concentrate on the quantitative analysis of serotonin and various peptides in prostatic malignancy, since high levels of constitutive secretion may not be appreciated by immunocytochemistry, as well as analysis of tumors for receptors to neuroendocrine products, which are necessary for these products to have a functional role. Finally, specific subtypes of neoplastic cells with neuroendocrine differentiation based on serotonin and peptide profiles should be analyzed.
引用
收藏
页码:1927 / 1931
页数:5
相关论文
共 74 条
[1]   PARTIAL CHARACTERIZATION OF A THYROID-STIMULATING HORMONE-LIKE PEPTIDE IN NEURO-ENDOCRINE CELLS OF THE HUMAN-PROSTATE GLAND [J].
ABRAHAMSSON, PA ;
LILJA, H .
PROSTATE, 1989, 14 (01) :71-81
[2]   PEPTIDE-HORMONEACTIVE AND SEROTONIN-IMMUNOREACTIVE TUMOR-CELLS IN CARCINOMA OF THE PROSTATE [J].
ABRAHAMSSON, PA ;
WADSTROM, LB ;
ALUMETS, J ;
FALKMER, S ;
GRIMELIUS, L .
PATHOLOGY RESEARCH AND PRACTICE, 1987, 182 (03) :298-307
[3]   PEPTIDE-HORMONE AND SEROTONIN-IMMUNOREACTIVE CELLS IN NORMAL AND HYPERPLASTIC PROSTATE-GLANDS [J].
ABRAHAMSSON, PA ;
WADSTROM, LB ;
ALUMETS, J ;
FALKMER, S ;
GRIMELIUS, L .
PATHOLOGY RESEARCH AND PRACTICE, 1986, 181 (06) :675-683
[4]   THE COURSE OF NEURO-ENDOCRINE DIFFERENTIATION IN PROSTATIC CARCINOMAS - AN IMMUNOHISTOCHEMICAL STUDY TESTING CHROMOGRANIN-A AS AN ENDOCRINE MARKER [J].
ABRAHAMSSON, PA ;
FALKMER, S ;
FALT, K ;
GRIMELIUS, L .
PATHOLOGY RESEARCH AND PRACTICE, 1989, 185 (03) :373-380
[5]  
ALMAGRO UA, 1986, ARCH PATHOL LAB MED, V110, P916
[6]   CHEMOTHERAPY FOR SMALL-CELL CARCINOMA OF PROSTATIC ORIGIN [J].
AMATO, RJ ;
LOGOTHETIS, CJ ;
HALLINAN, R ;
RO, JY ;
SELLA, A ;
DEXEUS, FH .
JOURNAL OF UROLOGY, 1992, 147 (03) :935-937
[7]  
APRIKIAN AG, 1993, CANCER, V71, P3952, DOI 10.1002/1097-0142(19930615)71:12<3952::AID-CNCR2820711226>3.0.CO
[8]  
2-X
[9]  
Bishop Anne E, 1990, Endocr Pathol, V1, P4, DOI 10.1007/BF02915151
[10]  
BLEICHNER JC, 1986, ARCH PATHOL LAB MED, V110, P1041